Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study
4 affiliations
- 1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America
- 2Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America
- 3Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
- 4Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
Abstract
Background: Fluoroquinolones (FQs) are a cornerstone of most all-oral, shorter regimens endorsed by the World Health Organization for the treatment of rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB). Knowledge of resistance to FQs can help guide regimen selection at the point of care. In settings where rapid testing for FQ resistance is unavailable, prediction models could support treatment decisions by identifying FQ resistance based on patient characteristics observable at the point of care. These prediction models have been typically developed and evaluated within a single country, and their generalizability across different geographic settings is unclear. Methods and findings: We used data from 5,175 patients with RR-TB and available FQ drug susceptibility testing (DST) results submitted to the TB Portals, an open-access data-sharing platform curated by the National Institute of Allergy and Infectious Diseases, from eight countries (Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Romania and Ukraine) between 2012 and 2024. Among these patients, 1,772 (34.2%) had FQ-resistant TB. We developed prediction models for FQ resistance using logistic regression, neural networks, and XGBoost. Models were evaluated under three strategies: (1) pooled models trained on multi-country data; (2) within-country models trained and evaluated using internal validation; and (3) cross-country models trained on subsets of countries and externally validated on held-out countries. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Across the three algorithms, pooled models showed moderate optimism-corrected discrimination, with AUROC ranging from 0.70 to 0.72 and AUPRC ranging from 0.57 to 0.59. Within-country models demonstrated slightly better discrimination, with AUROC and AUPRC reaching 0.8 for some countries. Cross-country external validation showed that performance loss from using a model trained on external data could be negligible to >0.1 AUPROC or AUROC, depending on the country and algorithm. A limited set of predictors, including case definition and treatment-history-related variables, were among the most consistently informative predictors, whereas demographic, comorbidity, social-risk, education, and employment variables showed more variable contributions across countries and algorithms. A limitation of our study is that the incidence of RR-TB and FQ resistance was relatively stable in our analysis dataset. Hence, the results may not generalize to scenarios with marked changes in MDR-TB dynamics. Conclusions: Predicting FQ resistance using demographic and clinical characteristics showed moderate ability to identify FQ resistance among patients with RR-TB, but their performance and predictor patterns varied across countries. Models developed for one or several countries cannot be assumed to generalize to other settings without rigorous external validation. These findings highlight the limitations of globally trained prediction models for RR/MDR-TB and underscore the need for locally informed prediction models to support clinical decision-making. Why was this study done?: What Did the Researchers Do and Find?: What do these findings mean?: In this cross-country study of more than 5,000 patients with rifampicin-resistant tuberculosis, Tianfang Shao and colleagues evaluate whether routinely available patient characteristics can help predict fluoroquinolone resistance when rapid testing is unavailable and find that model performance varies across countries, highlighting the importance of local validation before clinical use.
Related
- Clinical and laboratory determinants of treatment response and rifampicin resistance among Xpert MTB/RIF-confirmed extrapulmonary tuberculosis patients: A prospective study from Central India
- Excessive sample reagent incubation time increases the risk of false rifampin resistance results in Xpert(R) MTB/RIF Ultra tests performed on paucibacillary Mycobacterium tuberculosis sputum.
- Dynamic closure of the Mycobacterium tuberculosis InhA cofactor site reveals heterogeneous routes to isoniazid resistance
- A voltage-gated porin PPE1 regulates secretion and drug resistance in Mycobacterium tuberculosis
- Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosis
BibTeX
@article{shao2026predicting,
title = {{Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study}},
author = {Tianfang Shao and Mariana R. Neves and Molly Franke and Carole Mitnick and Jennifer Furin and Ted Cohen and Reza Yaesoubi},
journal = {PLOS Medicine},
year = {2026},
month = sep,
doi = {10.1371/journal.pmed.1004965},
url = {https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004965},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study
AU - Tianfang Shao
AU - Mariana R. Neves
AU - Molly Franke
AU - Carole Mitnick
AU - Jennifer Furin
AU - Ted Cohen
AU - Reza Yaesoubi
PY - 2026
DA - 2026/09/15
JO - PLOS Medicine
DO - 10.1371/journal.pmed.1004965
UR - https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004965
AB - Background: Fluoroquinolones (FQs) are a cornerstone of most all-oral, shorter regimens endorsed by the World Health Organization for the treatment of rifampicin-resistant or multidrug-resistant tuberculosis (RR/MDR-TB). Knowledge of resistance to FQs can help guide regimen selection at the point of care. In settings where rapid testing for FQ resistance is unavailable, prediction models could support treatment decisions by identifying FQ resistance based on patient characteristics observable at the point of care. These prediction models have been typically developed and evaluated within a single country, and their generalizability across different geographic settings is unclear. Methods and findings: We used data from 5,175 patients with RR-TB and available FQ drug susceptibility testing (DST) results submitted to the TB Portals, an open-access data-sharing platform curated by the National Institute of Allergy and Infectious Diseases, from eight countries (Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Romania and Ukraine) between 2012 and 2024. Among these patients, 1,772 (34.2%) had FQ-resistant TB. We developed prediction models for FQ resistance using logistic regression, neural networks, and XGBoost. Models were evaluated under three strategies: (1) pooled models trained on multi-country data; (2) within-country models trained and evaluated using internal validation; and (3) cross-country models trained on subsets of countries and externally validated on held-out countries. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Across the three algorithms, pooled models showed moderate optimism-corrected discrimination, with AUROC ranging from 0.70 to 0.72 and AUPRC ranging from 0.57 to 0.59. Within-country models demonstrated slightly better discrimination, with AUROC and AUPRC reaching 0.8 for some countries. Cross-country external validation showed that performance loss from using a model trained on external data could be negligible to >0.1 AUPROC or AUROC, depending on the country and algorithm. A limited set of predictors, including case definition and treatment-history-related variables, were among the most consistently informative predictors, whereas demographic, comorbidity, social-risk, education, and employment variables showed more variable contributions across countries and algorithms. A limitation of our study is that the incidence of RR-TB and FQ resistance was relatively stable in our analysis dataset. Hence, the results may not generalize to scenarios with marked changes in MDR-TB dynamics. Conclusions: Predicting FQ resistance using demographic and clinical characteristics showed moderate ability to identify FQ resistance among patients with RR-TB, but their performance and predictor patterns varied across countries. Models developed for one or several countries cannot be assumed to generalize to other settings without rigorous external validation. These findings highlight the limitations of globally trained prediction models for RR/MDR-TB and underscore the need for locally informed prediction models to support clinical decision-making. Why was this study done?: What Did the Researchers Do and Find?: What do these findings mean?: In this cross-country study of more than 5,000 patients with rifampicin-resistant tuberculosis, Tianfang Shao and colleagues evaluate whether routinely available patient characteristics can help predict fluoroquinolone resistance when rapid testing is unavailable and find that model performance varies across countries, highlighting the importance of local validation before clinical use.
SN - 1549-1676
ER -